The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 23, 2021

Filed:

Jun. 26, 2017
Applicant:

University of Iowa Research Foundation, Iowa City, IA (US);

Inventors:

Michael K. Schultz, Iowa City, IA (US);

Frances L. Johnson, Iowa City, IA (US);

Somya Kapoor, Iowa City, IA (US);

Dongyoul Lee, Iowa City, IA (US);

Mengshi Li, Iowa City, IA (US);

Molly Martin, Iowa City, IA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/04 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 38/08 (2019.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/437 (2006.01); A61K 31/4427 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 51/0482 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/437 (2013.01); A61K 31/4427 (2013.01); A61K 31/519 (2013.01); A61K 38/08 (2013.01); A61K 47/545 (2017.08); A61K 47/546 (2017.08); A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61K 51/048 (2013.01); A61K 51/0497 (2013.01); A61P 35/00 (2018.01);
Abstract

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).


Find Patent Forward Citations

Loading…